79
Pharma & HealthcareStrong Buy
HDFC Pharma And Healthcare
HDFC · Direct–Growth · rank #1 of 18 by Smart Score
Data updated
Trailing returns
1 Year
28.9%
+25.9% vs index
3 Years
—
5 Years
—
Since launch
32.1%
Year-by-year performance
2024
+52.2%+36.6% vs index
2025
+2.4%-5.3% vs index
2026
+26.7%+28.8% vs index
Why this score
HDFC Pharma And Healthcare scores 79/100 — the top-rated Pharma & Healthcare fund of 18 (Strong Buy). It stands out for sharpe ratio and alpha — beating 97% of peers on sharpe ratio. It has no major weak spot vs the category.
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
Sharpe ratio1.83 · 97th percentile in category
Alpha21.17 · 97th percentile in category
Sortino ratio2.63 · 97th percentile in category
Volatility14.02 · 72nd percentile in category
1Y return28.92% · 91st percentile in category
Fund size2939.98 Cr · 69th percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd9.66%
2.Divi's Laboratories Ltd9.14%
3.Max Healthcare Institute Ltd4.82%
4.Aster DM Healthcare Ltd4.7%
5.Lupin Ltd4.67%
37 disclosed equity positions · portfolio as of Jul 2026 · weights are % of total corpus.